### FORM 4

# Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL			
OMB Number:	umber: 3235-0287		
Estimated average burden			
hours per response	0.5		

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Investment Company Act of 1940 Instruction 1(b). (Print or Type Responses) 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person \* 2. Issuer Name and Ticker or Trading Symbol (Check all applicable) Kivel Richard REXAHN PHARMACEUTICALS, INC. [RNN] 10% Owner 3. Date of Earliest Transaction (Month/Day/Year) Other (specify below) C/O REXAHN PHARMACEUTICALS, 09/17/2010 INC., 15245 SHADY GROVE ROAD, SUITE 455 6. Individual or Joint/Group Filing(Check Applicable Line) 4. If Amendment, Date Original Filed(Month/Day/Year) Form filed by More than One Reporting Person ROCKVILLE, MD 20850 (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security 2. Transaction 2A. Deemed Transaction 4. Securities Acquired 5. Amount of Securities Beneficially 7. Nature (Instr. 3) Date Execution Date, if Code (A) or Disposed of (D) Owned Following Reported Ownership of Indirect (Instr. 8) (Month/Day/Year) any (Instr. 3, 4 and 5) Transaction(s) Form: Beneficial (Month/Day/Year Direct (D) (Instr. 3 and 4) Ownership or Indirect (Instr. 4) (A) or (I) Code (Ď) (Instr. 4) Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. Persons who respond to the collection of information SEC 1474 (9-02) contained in this form are not required to respond unless the form displays a currently valid OMB control number. Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 11. Nature 1. Title of 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and 8. Price of 9. Number of 10. Derivative Derivative Conversion Date Execution Date, if Transaction Expiration Date Amount of Derivative Ownership of Indirect Underlying Security or Exercise (Month/Day/Year Code Derivative (Month/Day/Year) Security Securities Form of Beneficial (Month/Day/Year) (Instr. 5) Beneficially (Instr. 3) Price of (Instr. 8) Securities Securities Derivative Ownership Acquired Derivative (Instr. 3 and 4) Owned Security: Instr. 4) Security (A) or Following Direct (D) Disposed of Reported or Indirect (D) Transaction(s) (T) (Instr 4) (Instr 3 4 (Instr 4) and 5)

Date

Exercisable

(1)

Expiration

09/17/2020

Date

Title

Stock

Amount

Number

Shares

20,000

\$ 0

20,000

D

#### **Reporting Owners**

\$ 1.19

09/17/2010

Reporting Owner Name / Address	Relationships				
reporting owner runte / runtess	Director	10% Owner	Officer	Other	
Kivel Richard C/O REXAHN PHARMACEUTICALS, INC.	X				
15245 SHADY GROVE ROAD, SUITE 455 ROCKVILLE, MD 20850					

#### **Signatures**

Stock Options

(right-

to-buy)

/s/ Tae Heum Jeong, as attorney-in-fact for Richard Kivel		10/22/2010	
**Signature of Reporting Person		Date	

#### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

(A)

20,000

(1) These options vest and become exercisable in full on September 17, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.